68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy

Trial Profile

68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 08 Jun 2018 Planned number of patients changed from 200 to 600.
    • 05 Jun 2018 Preliminary results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 21 May 2018 Results (n=6) of case series comparing of the two tests in men with BCR of CaP, were presented at the 113th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top